An International, Multicenter, Open-label, Randomized, Phase 3 Study of BLU-285 vs Regorafenib in Patients with Locally Advanced Unresectable or Metastatic Gastrointestinal Stromal Tumor (GIST) - VOYAGER

Blueprint Medicines Corporation0 个研究点目标入组 460 人开始时间: 2018年3月22日最近更新: 2021年10月18日

适应症

试验速览

阶段: 1 期
状态: 进行中（未招募）
发起方: Blueprint Medicines Corporation
入组人数: 460

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional clinical trial of medicinal product

入排标准

性别: All

入选标准

•1. Patients who are = 18 years of age.
•2. Patients who have GIST, which is histologically confirmed metastatic and/or
•unresectable (confirmed to be unresectable by a qualified surgeon).
•3. Patients who received imatinib and 1 or 2 other TKIs for the treatment of GIST, including TKIs used for adjuvant therapy. Each different TKI is counted once regardless of how often it was used, and if 2 different TKIs are used in combination, both TKIs are counted. Patients must have disease progression prior to enrollment. Prior use of other systemic and local therapies is not restricted.
•4. Patients who have an ECOG PS of 0 to 1.
•5. Patient, or legal guardian if permitted by local regulatory authorities, who provides informed consent to participate in the study
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 370
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 90

排除标准

•1. Patients who have received prior treatment with avapritinib or regorafenib.
•2. Patients who have previously received more than 3 different TKIs for the treatment of GIST, including TKIs used for adjuvant therapy. Each different TKI is counted once regardless of how often it was used, and if 2 different TKIs are used in combination, both TKIs are counted.
•3. Patients who are known to be both KIT and PDGRFa wild type.
•4. Patients who received any systemic anticancer therapy within 1 week before the first dose of study drug. Prior radiotherapy (including stereotactic radiotherapy) to major organs within 2 weeks of the first dose of study drug, or focal radiotherapy (including stereotactic radiotherapy), such as to bones, limbs, or other areas not involving major organs, within 3 days.
•5. Patients who have clinically significant, uncontrolled, cardiovascular disease, including congestive heart failure Grades II, III or IV according to the New York Heart Association classification, myocardial infarction or unstable angina within the previous 6 months, or uncontrolled hypertension.
•6. Patients who have experienced arterial thrombotic or embolic events such as cerebrovascular accident within 6 months before the first dose of study drug, or venous thrombotic events such as pulmonary embolism or deep vein thrombosis within 14 days before the first dose of study drug. Patients with venous thrombotic events such as pulmonary embolism or deep vein thrombosis = 14 days before the first dose of study drug are not excluded provided they are on stable doses of anticoagulation, or have completed the planned anti-coagulation regimen.
•7. Patients who have experienced any hemorrhage or bleeding event NCI CTCAE version 5.0 Grade 3 or higher within 4 weeks before the first dose of study drug.
•8. Patients who have a known risk of intracranial bleeding, such as a brain aneurysm that has not been removed or repaired, or a history of intracranial bleeding within one year prior to the first dose of study drug.
•9. Patients who have a symptomatic non-healing wound, ulcer, gastrointestinal perforation, or bone fracture.
•10. Patients who have poor organ function as defined by one or more laboratory parameters, as described in the protocol.
•11. Patients who have received neutrophil growth factor support within 14 days of the first dose of study drug.
•12. Patients who require therapy with a concomitant medication that is a strong inhibitor or strong or moderate inducer of CYP3A4.
•13. Patients who have had a major surgical procedure within 14 days of the first dose of study drug. Patient has significant traumatic injury within 28 days before the first dose of study drug.
•14. Patients who have a history of another primary malignancy that has been diagnosed or required therapy within 3 years before the first dose of study drug.
•15. Patients who have a history of a seizure disorder requiring anti-seizure medication.
•16. Patients who have metastases to the brain.
•17. Patients who are unwilling or unable to comply with scheduled visits, drug administration plan, laboratory tests, or other study procedures and study restrictions.
•18. Patients who have a QT interval corrected using Fridericia's formula (QTcF) of > 450 msec
•19. Women who are unwilling, if not postmenopausal or surgically sterile, to abstain from sexual intercourse or employ highly effective contraception from the time of the first dose of study drug and for at least 60 days after the la

研究者

发起方

Blueprint Medicines Corporation

相似试验

已完成

3 期

An International, Multicenter, Open-label, Randomized, Phase 3 Study of BLU 285 vs Regorafenib in Patients with Locally Advanced Unresectable or Metastatic Gastrointestinal Stromal Tumor (GIST)Gastrointestinal stromal tumor

NL-OMON48964Blueprint Medicines Corporation15

进行中（未招募）

1 期

A Study of Avapritinib vs Regorafenib in patients with Gastrointestinal and Solid Tumors.ocally Advanced Unresectable or Metastatic Gastrointestinal Stromal Tumor (GIST)MedDRA version: 21.1Level: LLTClassification code 10065252Term: Solid tumorSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10051066Term: Gastrointestinal stromal tumourSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)

EUCTR2017-003497-14-ATBlueprint Medicines Corporation460

进行中（未招募）

1 期

A Study of Avapritinib vs Regorafenib in patients with Gastrointestinal and Solid Tumors.ocally Advanced Unresectable or Metastatic Gastrointestinal Stromal Tumor (GIST)MedDRA version: 20.0Level: LLTClassification code 10065252Term: Solid tumorSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10051066Term: Gastrointestinal stromal tumourSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)

EUCTR2017-003497-14-FRBlueprint Medicines Corporation460

进行中（未招募）

1 期

A Study of Avapritinib vs Regorafenib in patients with Gastrointestinal and Solid Tumors.

EUCTR2017-003497-14-BEBlueprint Medicines Corporation460

进行中（未招募）

1 期

EUCTR2017-003497-14-NLBlueprint Medicines Corporation476